SwissMedic, Switzerlands equivalent of the FDA, permitted our LSD/end-of-life study to proceed for another year. We are pleased with the outcomes of the study so far. Recruitment has been challenging, but we are now treating our sixth subject out of an eventual 12 and a seventh subject is being screened for inclusion.